Latest News for HLCO
Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers
DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, is joining the American Board of Wound Management (ABWM) Foundation in celebrating the 10th Annual Wound Healing Awareness Month.
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced compelling preclinical results suggesting that topical treatment with human dermal…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HLCO.
U.S. House Trading
No House trades found for HLCO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.